Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Anlotinib Hydrochloride (AL3818) in Postoperative Adjuvant Therapy for High-grade Soft Tissue Sarcoma -- A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Trail

NCT03951571 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT03951571
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03951571 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Anlotinib Hydrochloride (AL3818) in Postoperative Adjuvant Therapy for High-grade Soft Tissue Sarcoma -- A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Trail
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Completed
Start date
May 13, 2019
Completion date
December 31, 2022
Enrollment
88 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

high grade sarcoma, soft tissue sarcoma adult